FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104460334> ?p ?o ?g. }

• W2104460334 endingPage "8382" @default.
• W2104460334 startingPage "8377" @default.
• W2104460334 abstract "Background: Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy worldwide. Cancer development and progression require inactivation of tumor suppressor genes and activation of proto-oncogenes. The well recognized mechanism of action demonstrated for chemotherapeutic agents is induction of apoptosis via reactivation of p53. In this context, we evaluate the efficacy of IV and oral routes of our novel PH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in affecting p53 profile in an OSCC rat model. Methods: In this study, 120 male rats were divided into 8 groups of 15 animals each. The new formulated DOX-MTX NP and free doxorubicin were IV and orally given to rats with 4-nitroquinoline-1-oxide induced OSCC. Results: Results showed that both DOX and DOX-MTX-NP caused significant increase in mRNA levels of P53 compared to the untreated group (p<0.000). With both DOX and DOX-MTX NP, the IV mode was more effective than the oral (gavage) route (p<0.000). Surprisingly, in oral mode, p53 mRNA was not affected in DOX treated groups (p>0.05), Nonetheless, both IV and oral administration of MTX-DOX NP showed superior activity (~3 fold) over free DOX in reactivation of p53 in OSCC (p<0.000). The effectiveness of oral route in group treated with nanodrug accounts for the enhanced bioavailability of nanoparticulated DOX-MTX compared to free DOX. Moreover, in treated groups, tumor stage was markedly related to the amount of p53 mRNA (p<0.05). Conclusion: Both oral and IV application of our novel nanodrug possesses superior activity over free DOX-in up-regulation of p53 in a OSCC model and this increase in p53 level associated with less aggressive tumors in our study. Although, impressive results obtained with IV form of nanodrug (-21 fold increase in p53 mRNA level) but both forms of nanodrug are effective in OSCC, with less toxicity normal cells." @default.
• W2104460334 created "2016-06-24" @default.
• W2104460334 creator A5001534314 @default.
• W2104460334 creator A5039914415 @default.
• W2104460334 creator A5043708378 @default.
• W2104460334 creator A5053329507 @default.
• W2104460334 creator A5057611294 @default.
• W2104460334 creator A5083824515 @default.
• W2104460334 date "2014-10-23" @default.
• W2104460334 modified "2023-10-14" @default.
• W2104460334 title "DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes" @default.
• W2104460334 cites W1543790510 @default.
• W2104460334 cites W1978793149 @default.
• W2104460334 cites W1980909702 @default.
• W2104460334 cites W1982956234 @default.
• W2104460334 cites W1989160700 @default.
• W2104460334 cites W1997129527 @default.
• W2104460334 cites W2003252913 @default.
• W2104460334 cites W2005433498 @default.
• W2104460334 cites W2007704906 @default.
• W2104460334 cites W2021692619 @default.
• W2104460334 cites W2034574681 @default.
• W2104460334 cites W2035132134 @default.
• W2104460334 cites W2050181086 @default.
• W2104460334 cites W2055532630 @default.
• W2104460334 cites W2058243578 @default.
• W2104460334 cites W2060984226 @default.
• W2104460334 cites W2070927090 @default.
• W2104460334 cites W2085080669 @default.
• W2104460334 cites W2094634520 @default.
• W2104460334 cites W2114348409 @default.
• W2104460334 cites W2117273788 @default.
• W2104460334 cites W2122523179 @default.
• W2104460334 cites W2132910064 @default.
• W2104460334 cites W2139887884 @default.
• W2104460334 cites W2145266132 @default.
• W2104460334 cites W2149599593 @default.
• W2104460334 cites W2167287546 @default.
• W2104460334 cites W2169398161 @default.
• W2104460334 cites W2638046965 @default.
• W2104460334 doi "https://doi.org/10.7314/apjcp.2014.15.19.8377" @default.
• W2104460334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25339032" @default.
• W2104460334 hasPublicationYear "2014" @default.
• W2104460334 type Work @default.
• W2104460334 sameAs 2104460334 @default.
• W2104460334 citedByCount "12" @default.
• W2104460334 countsByYear W21044603342015 @default.
• W2104460334 countsByYear W21044603342016 @default.
• W2104460334 countsByYear W21044603342017 @default.
• W2104460334 countsByYear W21044603342020 @default.
• W2104460334 countsByYear W21044603342022 @default.
• W2104460334 crossrefType "journal-article" @default.
• W2104460334 hasAuthorship W2104460334A5001534314 @default.
• W2104460334 hasAuthorship W2104460334A5039914415 @default.
• W2104460334 hasAuthorship W2104460334A5043708378 @default.
• W2104460334 hasAuthorship W2104460334A5053329507 @default.
• W2104460334 hasAuthorship W2104460334A5057611294 @default.
• W2104460334 hasAuthorship W2104460334A5083824515 @default.
• W2104460334 hasBestOaLocation W21044603341 @default.
• W2104460334 hasConcept C104317684 @default.
• W2104460334 hasConcept C105580179 @default.
• W2104460334 hasConcept C121608353 @default.
• W2104460334 hasConcept C126322002 @default.
• W2104460334 hasConcept C151730666 @default.
• W2104460334 hasConcept C181389837 @default.
• W2104460334 hasConcept C185592680 @default.
• W2104460334 hasConcept C190283241 @default.
• W2104460334 hasConcept C203014093 @default.
• W2104460334 hasConcept C2776694085 @default.
• W2104460334 hasConcept C2777056448 @default.
• W2104460334 hasConcept C2779343474 @default.
• W2104460334 hasConcept C2781059491 @default.
• W2104460334 hasConcept C2781303535 @default.
• W2104460334 hasConcept C502942594 @default.
• W2104460334 hasConcept C55493867 @default.
• W2104460334 hasConcept C71924100 @default.
• W2104460334 hasConcept C86803240 @default.
• W2104460334 hasConcept C98274493 @default.
• W2104460334 hasConceptScore W2104460334C104317684 @default.
• W2104460334 hasConceptScore W2104460334C105580179 @default.
• W2104460334 hasConceptScore W2104460334C121608353 @default.
• W2104460334 hasConceptScore W2104460334C126322002 @default.
• W2104460334 hasConceptScore W2104460334C151730666 @default.
• W2104460334 hasConceptScore W2104460334C181389837 @default.
• W2104460334 hasConceptScore W2104460334C185592680 @default.
• W2104460334 hasConceptScore W2104460334C190283241 @default.
• W2104460334 hasConceptScore W2104460334C203014093 @default.
• W2104460334 hasConceptScore W2104460334C2776694085 @default.
• W2104460334 hasConceptScore W2104460334C2777056448 @default.
• W2104460334 hasConceptScore W2104460334C2779343474 @default.
• W2104460334 hasConceptScore W2104460334C2781059491 @default.
• W2104460334 hasConceptScore W2104460334C2781303535 @default.
• W2104460334 hasConceptScore W2104460334C502942594 @default.
• W2104460334 hasConceptScore W2104460334C55493867 @default.
• W2104460334 hasConceptScore W2104460334C71924100 @default.
• W2104460334 hasConceptScore W2104460334C86803240 @default.
• W2104460334 hasConceptScore W2104460334C98274493 @default.
• W2104460334 hasIssue "19" @default.

• next